Aiforia Technologies plc (HEL:AIFORIA), a provider of AI-assisted medical software solutions, on Tuesday announced the release of a new CE-IVD marked clinical AI solution for breast cancer grading.

The solution is part of the Aiforia Breast Cancer Suite, which includes existing CE-IVD marked models for breast cancer biomarkers and the Aiforia Clinical Suite Viewer.

Aiforia's platform provides a fully digital diagnostic workflow by supporting pathologists with five AI models. It identifies invasive carcinoma and ductal carcinoma in situ, and scores key parameters such as mitotic count, tubular formation and nuclear pleomorphism based on the Nottingham Grading System.

The solution addresses common issues in manual grading, including variability and time inefficiencies. According to CEO Jukka Tapaninen, it enhances diagnostic accuracy and consistency and reduces time spent on histological grading.

Aiforia positions this launch as a step toward delivering the most comprehensive AI-based breast cancer diagnostics suite on the market.